Back to top

Analyst Blog

On Apr 8, we issued an updated research report on AmSurg Corporation (AMSG - Analyst Report) – a leading operator of single-specialty practice-based ambulatory surgery centers (ASCs). Despite uncertain economic conditions and high unemployment, we are encouraged by AmSurg’s fourth-quarter results that squarely beat the Zacks Consensus Estimate.

AmSurg’s fourth-quarter 2013 adjusted earnings per share (EPS) of 60 cents surged 22% year over year marking its third consecutive quarter of double-digit growth. EPS also steered ahead of the Zacks Consensus Estimate of 57 cents and exceeded the company’s guidance range of 56−58 cents. Revenues increased 17% to $284.6 million beating the Zacks Consensus Estimate of $283.0 million.

Fourth-quarter 2013 revenues were encouraging owing to strong growth across all categories. Net revenue per procedure showed an improvement, driven by a combination of mix change due to an increase in the number of multispecialty centers as a percentage of center mix. Although same-center revenues increased a mere 2% on a year-over-year basis, the company is confident about figures rising further in the next fiscal as Ophthalmology and GI continue to perform well.

We are also encouraged with the company’s newly formed joint venture with a hospital system and expect AmSurg to go ahead with its acquisition pipeline, supported by a strong cash position. Government agencies have undertaken initiatives to curtail healthcare expenditure, thereby resulting in a shift toward ambulatory surgery centers from admission to traditional hospitals.

However, AmSurg is encountering several challenges in the form of reimbursement issues and economic uncertainty. All of these collectively result in deferring elective procedures, along with a decline in doctor visits by patients, which in turn, leads to lower surgical volume.

AmSurg currently carries a ZacksRank #3 (Hold). Other stocks worth considering in the broader medical sector are Enzymotec Ltd. (ENZY - Snapshot Report), St. Jude Medical Inc. (STJ - Analyst Report) and Covidien plc (COV - Analyst Report). While Enzymotec holds a Zacks Rank #1 (Strong Buy), St. Jude Medical and Covidien carry a Zacks Rank #2 (Buy).

Read the Full Research Report on COV
Read the Full Research Report on STJ
Read the Full Research Report on AMSG
Read the Full Research Report on ENZY


Zacks Investment Research

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%